Bristol-Myers Squibb Company vs GILEAD SCIENCES, INC., two Drug Manufacturers stocks. A side-by-side on valuation, growth, margins, returns, and what each price is betting.
Where BMY and GILD diverge most: on altman z (solvency), BMY reads 2.12 and GILD reads 7.23; on ev/ebitda, BMY reads 45.6 and GILD reads 17.3. The rest of the comparable metrics sit closer together. What BMY's price implies is a bet that sits within the historical range (whole-company basis). What GILD's price implies is a bet that sits within the historical range (whole-company basis). The bull and bear cases for each are in their full reports below.
| Metric | BMY | GILD |
|---|---|---|
| Price | $62.09 | $129.35 |
| Market cap | $127.1B | $162.2B |
| Sector | Drug Manufacturers | Drug Manufacturers |
| Stage | Mature | Mature |
| Implied growth (priced in) | — | +1.7% |
| P/E | 17.4 | 17.6 |
| P/B | 6.32 | 6.90 |
| P/S | 2.62 | 5.45 |
| EV/EBITDA | 45.6 | 17.3 |
| Revenue growth | +1.8% | +3.5% |
| Operating margin | — | 37.2% |
| Net margin | 15.0% | 31.0% |
| Return on equity | 36.2% | 39.2% |
| Return on assets | 8.4% | 16.4% |
| Return on invested capital | — | 17.3% |
| FCF yield | 9.4% | 6.3% |
| Dividend yield | 4.0% | 2.4% |
| Debt / equity | 2.31 | 1.00 |
| Current ratio | 1.42 | 1.97 |
| Altman Z (solvency) | 2.12 | 7.23 |
| Piotroski F (quality) | 5 / 9 | 6 / 9 |
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
The stronger value is highlighted per metric where one is strictly better on that single number; it is not an overall verdict on either company. For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.